The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Determination of the activated form of the progesterone receptor (PR) in endometrial cancer (EC).
Dinny Graham
Consultant or Advisory Role - Arno Therapeutics
Honoraria - Arno Therapeutics
Jacques Bosq
Consultant or Advisory Role - Invivis
Jean-Michel Caillaud
No relevant relationships to disclose
Matthew A. Powell
Consultant or Advisory Role - Arno Therapeutics; Eisai; Merck
Eric Leblanc
Consultant or Advisory Role - Arno Therapeutics
Honoraria - Arno Therapeutics
Keiichi Fujiwara
Consultant or Advisory Role - Arno Therapeutics
Thomas J. Herzog
Consultant or Advisory Role - Arno Therapeutics
Bradley J. Monk
Consultant or Advisory Role - Arno Therapeutics
Honoraria - Arno Therapeutics
Christine Clarke
No relevant relationships to disclose
Alexander A. Zukiwski
Employment or Leadership Position - Arno Therapeutics
Consultant or Advisory Role - Invivis (U)
Stock Ownership - Arno Therapeutics
Research Funding - Arno Therapeutics
Erard M. Gilles
Employment or Leadership Position - Invivis
Consultant or Advisory Role - Arno Therapeutics
Stock Ownership - Invivis
Robert L. Coleman
Consultant or Advisory Role - Arno Therapeutics; AstraZeneca; Esperance Pharmaceuticals; MedImmune; Merck; Novartis; Roche